Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Blue Bird Corp (NQ: BLBD )

40.08 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Blue Bird Corp

< Previous 1 2 3 4 5 Next >
Blue Bird to Report Fiscal 2024 Fourth Quarter and Full Year Results on November 25, 2024
From Blue Bird Corporation
Via Business Wire
Blue Bird Appoints Edward Hightower to its Board of Directors
From Blue Bird Corporation
Via Business Wire
Blue Bird Announces FY2024 Preliminary Unit Sales and Revenue
From Blue Bird Corporation
Via Business Wire
Blue Bird Delivers First Fleet of Propane-Powered Buses to School District of Philadelphia
From Blue Bird Corporation
Via Business Wire
Blue Bird Applauds EPA’s $965 Million Clean School Bus Funding to Accelerate Adoption of Zero-Emission Student Transportation
From Blue Bird Corporation
Via Business Wire
Blue Bird Announces Resignation of President; Phil Horlock to Remain as President and CEO
From Blue Bird Corporation
Via Business Wire
Blue Bird Delivers its 2,000th Electric School Bus
From Blue Bird Corporation
Via Business Wire
Blue Bird Reports Fiscal 2024 Third Quarter Record Results; Raises 2024 Guidance and Long-Term Outlook
From Blue Bird Corporation
Via Business Wire
Blue Bird Announces CEO and Chairman Transition Plan
From Blue Bird Corporation
Via Business Wire
Blue Bird and Generate Capital Appoint General Manager for Clean Bus Solutions Joint Venture
From Blue Bird Corporation and Generate Capital
Via Business Wire
Blue Bird to Report Fiscal 2024 Third Quarter Results on August 7, 2024
From Blue Bird Corporation
Via Business Wire
Blue Bird Selected to Receive $80 Million Federal Grant to Expand Electric Vehicle Manufacturing
From Blue Bird Corporation
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Blue Bird Corporation (BLBD) (f/k/a Hennessy Capital Acquisition Corp.)
From Glancy Prongay & Murray LLP
Via Business Wire
Blue Bird’s Gurminder Bedi Steps Down from Board of Directors After Long Tenure
From Blue Bird Corporation
Via Business Wire
Blue Bird Launches Most Comprehensive School Bus Safety Upgrades in its History
From Blue Bird Corporation
Via Business Wire
Blue Bird Announces Ratification of Collective Bargaining Agreement by United Steelworkers
From Blue Bird Corporation
Via Business Wire
Blue Bird Debuts Electric Step Van at 2024 Advanced Clean Transportation (ACT) Expo
From Blue Bird Corporation
Via Business Wire
Blue Bird Expands Leadership of Sales and Marketing Organization
From Blue Bird Corporation
Via Business Wire
Blue Bird Reports Fiscal 2024 Second Quarter Record Results; Raises 2024 Guidance and Long-Term Outlook
From Blue Bird Corporation
Via Business Wire
Blue Bird Extends Exclusive Clean School Bus Collaboration with Ford Component Sales and ROUSH CleanTech to 2030
From Blue Bird Corporation
Via Business Wire
Blue Bird to Report Fiscal 2024 Second Quarter Results on May 8, 2024
From Blue Bird Corporation
Via Business Wire
Blue Bird Corp. (NASDAQ: BLBD) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
Blue Bird Corp. (NASDAQ: BLBD) Records 52-Week High Thursday Morning
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
Blue Bird Corp. (NASDAQ: BLBD) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Blue Bird Announces Launch of Secondary Public Offering
From Blue Bird Corporation
Via Business Wire
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
Exposures Product Safety
Blue Bird Corp. (NASDAQ: BLBD) Records 52-Week High Thursday Morning
Via Investor Brand Network
Topics Energy
Exposures Fossil Fuels
Blue Bird Reports Fiscal 2024 First Quarter Record Results; Raises 2024 Guidance
From Blue Bird Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.